SEC Tracker
Get the app

Savara SVRA

Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment

Form
8-K
Filed
Period
Importance
Routine
Document
8-K
Exhibit 99.1
Press release
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Savara files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Opko Health OPK public float $540M, Dec 31, 2025
  2. Iovance Biotherapeutics IOVA public float $535M, Jun 30, 2025
  3. Elite Pharmaceuticals ELTP public float $534M, Sep 30, 2025
  4. Xencor XNCR public float $556M, Jun 30, 2025
  5. Evolus EOLS public float $560M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.